KRAS and neoplasm: In addition, KRAS variants were detectable in plasma as early as 10 months before progression was assessed by radiological methods.[6] Therefore, combining serial tumor biopsy, liquid biopsy, and radiologic imaging could help to define mechanisms of drug resistance and to guide selection of therapeutic strategies.